Better Context → Better Decisions
Context counts in life sciences. The Celltelligence analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access can use our library to search all of the content already delivered to their inbox. If you think a colleague would enjoy receiving our content, reach out to the Celltelligence team to make it happen.
Free
Posted in: Autologous, BCMA, CAR-T, CD19 Oct 27 | 2021Kymriah’s Sales Continue to Decline; Novartis Files Kymriah for R/R FL in the US and EU; Why is Novartis Prioritizing YTB323 in 2L DLBCL? Novartis Q3 2021 Earnings Call SummaryAccess Free Blast
Free
Posted in: Autologous, TCR Oct 26 | 2021Thoughts on TCR2 Tx’s Collaboration With BMSAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T Oct 22 | 2021JNJ Prepares for Cilta-cel’s Upcoming Approval; Could JNJ’s / Legend’s New Patient-Focused Digital Platform and Sales Force Strategy Position Cilta-cel for a Successful Launch?Access Free Blast
Free
Posted in: Allogeneic, Autologous, TCR Oct 21 | 2021TCR2 Tx Pivots Away from Liquid Tumors; Will Enhanced TRuC-Ts Improve Efficacy in Solid Tumors? TCR2 Tx Explores New Targets and Allogeneic Candidates; TCR2 Tx’s R&D DayAccess Free Blast
Free
Posted in: Autologous, BCMA Oct 19 | 2021Cilta-cel on Track to Gain FDA Approval in Q4 2021; JNJ Q3 2021 Earnings Call SummaryAccess Free Blast
Free
Posted in: Allogeneic, Autologous, BCMA, CAR-T Oct 19 | 2021Cilta-cel’s Potential Off-Label Use in the US; Could BMS’s KarMMa-3 Trial Design Limit Abecma’s Targetable Population? Legend / JNJ Pivot to Earlier Lines; Legend Explores Allogeneics, CAR-NKs, and Novel Solid Tumor Targets; Legend’s R&D DayAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T, CD19 Oct 15 | 2021No Cell Therapy Updates in October's CHMP HighlightsAccess Free Blast
Free
Posted in: Allogeneic, Autologous, CAR-T, CD19 Oct 14 | 2021CRISPR Tx’s CTX110 Reports a Comparable Efficacy and Safety Profile to Autologous CD19 CAR-Ts; 2seventy’s Launch Delayed to November 2021; bluebird and Poseida Appoint New Leadership RolesAccess Free Blast
Free
Posted in: Autologous, CAR-T Oct 13 | 2021Thoughts on Breyanzi's Continuing EU Regulatory Delays; Will Kymriah Receive a Positive CHMP Opinion for R/R FL in December 2021? No Updates for Tecartus, Cilta-cel, and Yescarta in October’s CHMP AgendaAccess Free Blast
Free
Posted in: Allogeneic, CAR-T Oct 08 | 2021Allogene’s AlloCAR-T Programs Placed on Clinical Hold by the FDAAccess Free Blast
Free
Posted in: Autologous, TCR Oct 05 | 2021T-Cure Partners With Atlas to Develop a KK-LC-1 Diagnostic TestAccess Free Blast
Free
Posted in: Autologous, CAR-T Oct 04 | 2021BMS Bets on Digital Health Coaching Following CAR-T Treatment to Improve Quality of Life OutcomesAccess Free Blast
Free
Posted in: Autologous, CAR-T, CD19 Oct 04 | 2021Gilead’s (Kite) Tecartus Receives FDA Approval for R/R Adult ALLAccess Free Blast
Free
Posted in: Allogeneic, Autologous, CAR-T Oct 04 | 2021Thoughts On the Evolution of the Cell Therapy Landscape; Will Traditional αβ CAR-T Cells be Replaced by Novel Cell Types?Access Free BlastFree
Posted in: Autologous, CAR-T, CD19 Oct 02 | 2021Tecartus Receives FDA Approval for R/R Adult ALLAccess Free BlastFree
Posted in: CAR-T, CD19 Oct 01 | 2021Gilead Files an sBLA for Yescarta in 2L R/R DLBCLAccess Free Blast
Free
Posted in: TCR Sep 28 | 2021Ziopharm’s TCR-T Program Pushed Back to H1 2022; Ziopharm Sheds Over 50% of Its WorkforceAccess Free Blast
Free
Posted in: Allogeneic, CAR-T Sep 27 | 2021Precision Appoints Michael Amoroso as Their New CEOAccess Free Blast
Free
Posted in: Autologous, BCMA, CD19 Sep 24 | 2021Will 2seventy’s Novel Pipeline Assets be Innovative Enough? 2seventy’s Research Deep Dive Investor Event SummaryAccess Free BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.